NCT00270387View on ClinicalTrials.gov

A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

January 31, 2001

Study Completion Date

January 31, 2002

Conditions

CardiomyopathiesHeart Failure, CongestiveDyspnea, Paroxysma

Interventions

DRUG

Natrecor (nesiritide)

All Listed Sponsors

lead

Scios, Inc.

INDUSTRY

NCT00270387 - A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy | Biotech Hunter | Biotech Hunter